Shi-Yong Sun
Emory & Henry College
H-index: 72
North America-United States
Top articles of Shi-Yong Sun
Targeting DNA topoisomerase II to manage acquired resistance to third generation EGFR tyrosine kinase inhibitors in the treatment of EGFR mutant NSCLC
Cancer Research
2024/3/22
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models
The Journal of Clinical Investigation
2024/3/7
ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression
Neoplasia
2023/8/1
Wen Zhao
H-Index: 1
Shi-Yong Sun
H-Index: 35
Darolutamide reverses osimertinib resistance in non-small cell lung cancer
Cancer Research
2023/4/4
Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors
2023/3/1
Shi-Yong Sun
H-Index: 35
Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1 (Apr, 117, 2022)
Cancer Gene Therapy
2022/11
Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1
Cancer gene therapy
2022/11
Therapeutic potential of the novel Bcl‐2/Bcl‐XL dual inhibitor, APG1252, alone or in combination against non‐small cell lung cancer
Molecular Carcinogenesis
2022/11
Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors
2022/10
Shi-Yong Sun
H-Index: 35
Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma …
Anti-Cancer Drugs
2022/10/1
Multiplexed protein profiling reveals spatial subcellular signaling networks
Iscience
2022/9/16
Mayar Allam
H-Index: 4
Shi-Yong Sun
H-Index: 35
From pancreatic cancer to lung cancer, ZIP4’s oncogenic function continues
Annals of Pancreatic Cancer
2022/7/30
Shi-Yong Sun
H-Index: 35
Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutations
2022/7/26
Shi-Yong Sun
H-Index: 35
Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis
Neoplasia
2022/7/1
Shaomeng Wang
H-Index: 52
Shi-Yong Sun
H-Index: 35
Therapeutic potential of the novel SHP2 degrader, SHP2-D26, alone or in combination, in the treatment of lung cancer
Cancer Research
2022/6/15
Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both
Oncogene
2022/3/18
Shi-Yong Sun
H-Index: 35
The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC …
American Journal of Cancer Research
2022
Shaomeng Wang
H-Index: 52
Shi-Yong Sun
H-Index: 35
The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition
Pharmacological research
2022/1/1
Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib
Oncogene
2021/12/9
Zhen Chen
H-Index: 13
Shi-Yong Sun
H-Index: 35
Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis
Cancer Letters
2021/10/28
